In vitro activity of thiacetazone on mycobacterial species belonging to the Mycobacterium tuberculosis complex

International Journal of Tuberculosis and Lung Disease

Volumn 6, Issue 10, 2002, Pages 933-935

  Abate, Getahun ^a   Koivula, T ^a   Hoffner, S E ^a  

^a c/o Abraham Aseffa ^*  (Ethiopia)

Author keywords

M. africanum; M. tuberculosis; MIC; Thiacetazone

Indexed keywords

THIOACETAZONE;

ANTIBACTERIAL ACTIVITY; ARTICLE; BACTERIAL GROWTH; BACTERIAL STRAIN; DRUG INDUCED DISEASE; HUMAN; MINIMUM INHIBITORY CONCENTRATION; MYCOBACTERIUM TUBERCULOSIS; NONHUMAN; PRIORITY JOURNAL;

ANTITUBERCULAR AGENTS; COLONY COUNT, MICROBIAL; DOSE-RESPONSE RELATIONSHIP, DRUG; HUMANS; MICROBIAL SENSITIVITY TESTS; MYCOBACTERIUM; MYCOBACTERIUM TUBERCULOSIS; THIOACETAZONE;

EID: 0036800595     PISSN: 10273719     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (10)

1. World Health Organization. Guidelines for the management of drug-resistant tuberculosis. WHO/TB/96.210 (Rev. 1). Geneva: WHO
2. Elliott A M, Foster S D. Thioacetazone: time to call a halt? Tubercle Lung Dis 1996; 77: 27-29.
3. Bercion R, Kuaban C. Initial resistance to anti-tuberculosis drugs in Yaounde, Cameroon in 1995. Int J Tuberc Lung Dis 1997; 1: 110-114.
4. Van-Gorkom J, Kibuga D K. Cost-effectiveness and total costs of three alternative strategies for the prevention and management of severe skin reactions attributable to thiacetazone in the treatment of human immunodeficiency virus positive patients with tuberculosis. Tubercle Lung Dis 1996; 77: 30-36.
5. Källenius G, Koivula T, Ghebremichael S, et al. Evolution and clonal traits of Mycobacterium tuberculosis complex in Guinea-Bissau. J Clin Microbiol 1999; 37: 3872-3878.
6. Kent P T, Kubica G. Public health mycobacteriology: a guide for the level III laboratory. Atlanta, GA: US Department of Health and Human Services, Centers for Disease Control, 1985.
7. David H L, Jahan M T, Jumin A, Grandry J, Lehman E H. Numerical taxonomy analysis of Mycobacterium africanum. Int J Syst Bacteriol 1978; 28: 467-472.
8. Jagannath C, Allauden H S, Hunter R L. Activities of poloxamer CRL8131 against Mycobacterium tuberculosis in vitro and in vivo. Antimicrob Agents Chemother 1995; 39: 1349-1354.
9. Kondo N, Kuwahara-Arai K, Kuroda-Murakami H, Tateda-Suzuki E, Hiramatsu K. Eagle-type methicillin resistance: new phenotype of high methicillin resistance under mec regulator gene control. Antimicrob Agents Chemother 2001; 45: 815-824.
10. Furin J J, Mitnick C D, Shin S S, et al. Occurrence of serious side effects in patients receiving community-based therapy for multidrug-resistant tuberculosis. Int J Tuberc Lung Dis 2001; 5: 648-655.